Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?
作者信息
Cervelli Nazzareno, Tocci Giuliano, Ferri Claudio
机构信息
Department of MeSVA, University of L'Aquila, Coppito, 67100, L'Aquila, Italy.
The Italian Society of Hypertension (SIIA), Rome, Italy.
出版信息
High Blood Press Cardiovasc Prev. 2018 Mar;25(1):5-7. doi: 10.1007/s40292-017-0244-x. Epub 2018 Jan 5.
PMID:29305812
Abstract
摘要
Zotero 插件